PARP Inhibitors vs Chemotherapy — Clinical Trial Comparison
PARP Inhibitors
Exploit DNA repair defects in BRCA/HRD tumours
VS
Chemotherapy
Cytotoxic drugs killing rapidly dividing cells
PARP inhibitors are one of the greatest success stories of precision oncology. By exploiting a specific vulnerability in cancer cells with defective DNA repair (BRCA mutations or homologous recombination deficiency), drugs like olaparib, niraparib, and talazoparib can be highly effective with fewer side effects than traditional chemotherapy. UK clinical trials are exploring PARP inhibitors across ovarian, breast, prostate, and pancreatic cancers — often in direct comparison with or as maintenance after chemotherapy.
Key Differences at a Glance
| Feature | PARP Inhibitors | Chemotherapy |
|---|---|---|
| Mechanism | Blocks PARP enzyme, causing synthetic lethality in cells with defective homologous recombination repair (HRR) | Directly damages DNA or disrupts cell division in all rapidly dividing cells |
| Target specificity | Highly specific — requires BRCA mutation or HRD positivity for best results | Non-specific — works regardless of genetic profile |
| Genetic testing required | Yes — BRCA1/2 germline and somatic, HRD testing, genomic instability score | Not usually required |
| Common drugs in trials | Olaparib (Lynparza), niraparib (Zejula), talazoparib (Talzenna), rucaparib (Rubraca) | Carboplatin, paclitaxel, cisplatin, gemcitabine, liposomal doxorubicin |
| Administration | Oral tablets — taken continuously at home | IV infusion — cycles every 1–3 weeks in hospital |
| Side effect profile | Generally milder — nausea, fatigue, anaemia, thrombocytopenia | Broader — hair loss, severe nausea, myelosuppression, neuropathy |
Clinical Trial Availability
| Trial Aspect | PARP Inhibitors | Chemotherapy |
|---|---|---|
| UK trials actively recruiting | 60–100 studies | 150–250 studies |
| Most common phases | Phase 2–3 | Phase 2–3 |
| Top cancers studied | Ovarian, breast (triple-negative, HER2-), prostate (mCRPC), pancreatic, peritoneal | All cancer types |
| Biomarker requirements | BRCA1/2 mutation, HRD positivity, HRR gene mutations required for most trials | Minimal biomarker requirements |
| Maintenance trials | Major focus — PARP after chemo response in ovarian cancer | Less emphasis on maintenance approach |
| Combination trials | PARP + immunotherapy, PARP + anti-angiogenic, PARP + targeted therapy | Chemo + targeted, chemo + immuno, chemo + radiation |
Exciting Emerging Treatments
PARP Inhibitors Trials
- PARP + immunotherapy — combining DNA damage with immune activation
- PARP + anti-angiogenic agents — olaparib + bevacitazumab dual approach
- Earlier-line use — moving PARP from recurrence to first-line and adjuvant
- PARP in prostate cancer — expanding beyond ovarian/breast to HRR-mutant prostate
- Novel PARP inhibitors — next-generation agents with better selectivity
- PARP in pancreatic cancer — targeting BRCA-mutant pancreatic tumours
Chemotherapy Trials
- Dose-optimised chemotherapy — finding minimum effective doses
- Chemo + PARP inhibitor sequencing — chemo to induce response, PARPi to maintain
- Antibody-drug conjugates — precision chemo delivery
- Intraperitoneal chemotherapy — direct delivery for ovarian cancer
- Chemo + immunotherapy — using chemo to prime immune response
- Adaptive dosing — adjusting chemo based on real-time response
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
PARP Inhibitors Trial Criteria
- Confirmed BRCA1/2 mutation (germline or somatic) and/or HRD positivity
- Appropriate cancer type (ovarian, breast, prostate, pancreatic)
- Prior treatment requirements met (e.g., platinum-sensitive relapse)
- Adequate blood counts (particularly important — PARPi can cause anaemia)
- No prior PARP inhibitor treatment (for most trials)
- Measurable disease or CA-125 response criteria
Chemotherapy Trial Criteria
- Confirmed cancer diagnosis with measurable disease
- Adequate organ function and blood counts
- ECOG performance status 0–2
- No uncontrolled comorbidities
- Recovery from prior treatment toxicities
- Appropriate line of therapy
PARP Inhibitor Trials
Find actively recruiting PARP inhibitor clinical trials across the UK
PARP Inhibitor TrialsFrequently Asked Questions
Do I need a BRCA test to join a PARP inhibitor trial?
Yes, virtually all PARP inhibitor trials require genetic testing. Most need either a germline BRCA mutation (inherited) or somatic BRCA mutation (tumour-specific). Many also accept broader homologous recombination deficiency (HRD) testing. Your oncologist can arrange this through the NHS or privately.
Can PARP inhibitors replace chemotherapy entirely?
In some situations, yes — particularly as maintenance therapy after chemotherapy response in ovarian cancer. For first-line treatment, PARP inhibitors are usually given after or alongside chemotherapy rather than replacing it entirely. Trials are exploring whether PARP inhibitors can be used earlier and even replace chemo in selected patients.
What cancers can PARP inhibitors treat beyond ovarian?
PARP inhibitors are approved and in trials for ovarian, breast (especially triple-negative with BRCA), prostate (HRR-mutant mCRPC), and pancreatic cancer (BRCA-mutant). Research is expanding to other cancers with DNA repair defects, including some types of lung and endometrial cancer.